Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature

Bibliography

• Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23(2):192-202
   PubMed Web of Science ®Google Scholar
• Masjedi M, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 20022006. Int J Tuberc Lung Dis 2008;12(7):750-5
   PubMed Web of Science ®Google Scholar
• Organization WHO. WHO Global tuberculosis report. 2012. Available from: apps.who.int/iris/.../9789241564502_eng.pd
   Google Scholar
• Makhlouf HA, Helmy A, Fawzy E, et al. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol Int 2008;2(3):353-60
   PubMed Web of Science ®Google Scholar
• Gülbay BE, Gürkan ÖU, Yıldız ÖA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006;100(10):1834-42
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Mirsaeidi S, Amiri M, et al. Clinical and laboratory profile of patients with tuberculosis/HIV coinfection at a national referral centre: a case series. East Mediterr Health J 2008;14(2):283-91
   PubMedGoogle Scholar
• Shamaei M, Marjani M, Chitsaz E, et al. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. Int J Infect Dis 2009;13(5):e236-e40
   PubMed Web of Science ®Google Scholar
• Breen RA, Miller RF, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006;61(9):791-4
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167(11):1472-7
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Moradi A, Baghaei P, et al. Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy [Short communication]. Int J Tuberc Lung Dis 2011;15(4):547-50
   PubMed Web of Science ®Google Scholar
• Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45(10):1290-5
   PubMed Web of Science ®Google Scholar
• Metanat M, Sharifi-Mood B, Shahreki S, Dawoudi S. Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in Zahedan, Southeastern Iran. Iranian Red Crescent Med J 2012;14(1):53
   Web of Science ®Google Scholar
• Zaleskis R. Adverse effects of anti-tuberculosis chemotherapy. Eur Respir Dis 2006:47-9
   Google Scholar
• Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001;5(7):648-55
   PubMed Web of Science ®Google Scholar
• Guo N, Marra F, Fitzgerald J, et al. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis. Eur Respir J 2010;36(1):206-8
   PubMed Web of Science ®Google Scholar
• Gholami K, Kamali E, Hajiabdolbagh Mi SG. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract 2006;4(3):134-8
   PubMedGoogle Scholar
• Javadi MR, Shalviri G, Gholami K, et al. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf 2007;16(10):1104-10
   PubMed Web of Science ®Google Scholar
• Sharifzadeh M, Rasoulinejad M, Valipour F, et al. Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberclosis treatment. Pharmacol Res 2005;51(4):353-8
   PubMed Web of Science ®Google Scholar
• Taramian S, Joukar F, Asgharnezhad M, et al. Side effects of first-line antituberculosis drugs. J Guilan Univ Med Sci 2013;85(22):42-7
   Google Scholar
• Rasoulinejad M, Bouyer M, Emadi Kouchak H, et al. [Drug-induced complications of anti-tuberculosis drugs in HIV patients]. Tehran Univ Med J 2011;68(10):611-17; Article in Persian
   Google Scholar
• Afzali H, Taghavi N. [Evaluation of clinical and paraclinical signs and drugs side-effects in patients with Tuberculosis]. KAUMS J (FEYZ) 2002;5(4):86-96; Article in Persian
   Google Scholar
• Ayatollahi SAR, Khavendegaran F. [Prevalence of the side effects of anti-TB drugs in tubercular patients in Shiraz, 2001-2002]. Armaghane-Danesh 2004;9(33):53-61; Article in Persian
   Google Scholar
• Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther 2011;18(2):e29-34
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Chitsaz E, Tabatabaei V, et al. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases. Am J Ther 2011;18(5):343-9
   PubMed Web of Science ®Google Scholar
• Aminzadeh Z, Asl RT. A six months follow-up on children less than 6 years old in contact with smear positive tuberculosis patients, Varamin city, Tehran, Iran. Int J Prevent Med 2011;2(2):79
   Google Scholar
• Ataei B, Javadi A, Karimi I, et al. [Comparing effect and complication of two different therapeutic regimen with DOT’s strategy in spotum positive pulmonary tuberculosis]. J Isfahan Med School 2005;22(75):44-6; [Article in Persian]
   Google Scholar
• Baniasadi S, Eftekhari P, Tabarsi P, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010;22(10):1235-8
   PubMed Web of Science ®Google Scholar
• Hajibagheri K. [Extent of liver enzymes elevation in patients under treatment of tuberculosis]. Sci J Kudrestan Univ Med Sci 2003;6(23):12-15; [Article in Persian]
   Google Scholar
• Alavi-Naini R, Moghtaderi A, Metanat M, et al. Factors associated with mortality in tuberculosis patients. J Res Med Sci 2013;18(1):52-5
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Saber-Tehrani AS, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009;12(1):14
   PubMedGoogle Scholar
• Afsharian M, Meigouni S, Janbakhsh A, et al. Prevalence of probable drug-induced hepatitis following the treatment of tuberculosis in Kermanshah Sina Hospital (1996–2004). J Kermanshah Univ Med Sci 2007;11:3
   Google Scholar
• GhasemiBarghi R, HajAghaMohammadi A, Samimi R. Drug-induced hepatitis (Abundance and Outcome During Course of Tuberculosis Treatment): seven-year Study on 324 Patients with Positive Sputum in Iran. Govaresh 2011;16(2):134-8
   Google Scholar
• Khalili H, Dashti-Khavidaki S, Rasoolinejad M, et al. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. DARU J Pharm Sci 2009;17(3):163-7
   Google Scholar
• Baghaei P, Tabarsi P, Chitsaz E, et al. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther 2010;17(1):17-22
   PubMed Web of Science ®Google Scholar
• Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol 2004;4(2):167-70
   PubMed Web of Science ®Google Scholar
• Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infect Ther 2012;10(4):475-86
   PubMed Web of Science ®Google Scholar
• Lv X, Tang S, Xia Y, et al. Adverse reactions due to directly observed treatment strategy therapy in chinese tuberculosis patients: a prospective study. PLoS One 2013;8(6):e65037
   PubMed Web of Science ®Google Scholar
• Shinde KM, Pore SM, Bapat TR. Adverse reactions to first-line anti-tuberculous agents in hospitalised patients: pattern, causality, severity and risk factors. Indian J Med Specialities 2013;4(1):16-21
   Google Scholar
• Marra F, Marra C, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007;11(8):868-75
   PubMed Web of Science ®Google Scholar
• Hinderaker S, Ysykeeva J, Veen J, Enarson D. Serious adverse reactions in a tuberculosis programme setting in Kyrgyzstan [Notes from the field]. Int J Tuberc Lung Dis 2009;13(12):1560-2
   PubMed Web of Science ®Google Scholar
• Arbex MA, Varella MDCL, Siqueira HRD, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 2: second line drugs. J Bras Pneumol 2010;36(5):641-56
   PubMed Web of Science ®Google Scholar
• Arbex MA, Varella MDCL, Siqueira HRD, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs. J Bras Pneumol 2010;36(5):626-40
   PubMed Web of Science ®Google Scholar
• Xia YY, Zhan SY. [Systematic review of anti-tuberculosis drug induced adverse reactions in China]. Zhonghua Jie He He Hu Xi Za Zhi 2007;30(6):419-23
   PubMedGoogle Scholar
• Xia YY, Hu DY, Liu FY, et al. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health 2010;10:267
   PubMed Web of Science ®Google Scholar
• Lemos ACM, Matos ED. Multidrug-resistant tuberculosis. Braz J Infect Dis 2013;17(2):239-46
   PubMed Web of Science ®Google Scholar
• Karagoz T, Yazicioglu Mocin O, Pazarli P, et al. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. Tuberk Toraks 2009;57:383-92
   PubMedGoogle Scholar
• Shin S, Pasechnikov A, Gelmanova I, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007;11(12):1314-20
   PubMed Web of Science ®Google Scholar
• Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9(12):1373-7
   PubMed Web of Science ®Google Scholar
• Chhetri AK, Saha A, Verma SC, et al. A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokhara. JPMA 2008;58(10):531-6
   Google Scholar
• Singla R, Sharma SK, Mohan A, et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010;132:81-6
   PubMed Web of Science ®Google Scholar
• Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010;50(6):833-9
   PubMed Web of Science ®Google Scholar
• Heidari AA, Salim Bokharaee SH, Mojtabavi M, Heidari S. [The causes of treatment cessation in the patients suffering from pulmonary tuberculosis]. Med J Mashhad Univ Med Sci 2009;52(1):25-8; Article in Persian
   Google Scholar
• Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 2011;6(7):e21836
   PubMed Web of Science ®Google Scholar
• Anand A, Seth A, Paul M, Puri P. Risk factors of hepatotoxicity during anti-tuberculosis treatment. Med J Armed Forces India 2006;62(1):45-9
   Google Scholar
• Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010;50(6):840-2
   PubMed Web of Science ®Google Scholar
• Tahaoglu K, Atac G, Sevim T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001;5(1):65-9
   PubMed Web of Science ®Google Scholar
• Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm 1992;49(9):2229-32
   Web of Science ®Google Scholar